NCT03226418 2026-03-10Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid LeukemiaUniversity of NebraskaPhase 2 Completed75 enrolled 14 charts
NCT04214249 2026-03-04BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid LeukemiaNational Cancer Institute (NCI)Phase 2 Active not recruiting49 enrolled 32 charts